Get the Weekly Intelligence Brief — top committee picks every Sunday.
ENSG · NASDAQ · STOCK

Ensign Group (ENSG) Stock Analysis

Healthcare Updated September 17, 2026
$177.91
52W $141.58 – $218.00
64/100
$10.07B
26.3
0.69
AI Committee Verdict
Buy
64/100
Conviction: Moderate · 67% agreement · 6 analysts
+1.1%
-3.1%
0.35:1
Moderate
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is ENSG Bullish or Bearish?

Bullish. Innellis AI committee rates Ensign Group (ENSG) Buy with a composite score of 64/100 , based on 6 analysts with 67% agreement. Last updated September 17, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +11.49 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -8.51 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock. The main limiting factor is p/e of 27.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • ROE of 16.5% shows genuine earnings power backing the valuation — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock — Risk
  • News sentiment is positive (+0.25 across 4 articles, 14d) — News
Bear Case
  • P/E of 27.2 is moderate-to-rich — Value
  • Price-to-book of 4.5x prices in significant intangible value — Value
  • Price structure making lower highs and lower lows — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Trend and market structure agree -- coherent bearish picture — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 17, 2026
Overall Committee Score
64/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 18%
of 192 Healthcare peers
Value Analyst neutral
54 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 16.5% shows genuine earnings power backing the valuation
− P/E of 27.2 is moderate-to-rich
Growth Analyst bullish
75 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst neutral
42 / 100 · High confidence
Mixed or range-bound price action
− Price structure making lower highs and lower lows
Risk Analyst bullish
80 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 4 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2514.55)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 63.5 to 63.5.

Analyst-level changes:
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-09-16 to 2026-09-17 (1 day apart).

Technical Analysis

RSI (14)
43.6
Neutral
MACD Histogram
-0.214
Bearish Momentum
Trend Direction
Downtrend
Weekly: Sideways
Market Structure
Lh Ll
Support
$167.57
Resistance
$174.75
Bollinger %B
0.35
Inside Bands
Price vs Moving Averages
EMA 9
$173.39 Above
EMA 21
$174.61 Above
EMA 50
$174.77 Above
EMA 200
$175.99 Above

Fundamental Analysis

Valuation
61
Growth
68
Profitability
44
Financial Health
57
Cash Flow
70
Valuation
P/E Ratio 26.3×
P/B Ratio 4.10×
PEG Ratio 1.66
Dividend Yield 0.15%
52W High $218.00
52W Low $141.58
Quality & Growth
ROE 1541.3%
ROA 629.6%
Gross Margin 1414.2%
Operating Margin 851.9%
Revenue Growth YoY
Debt / Equity 0.92
AI Fundamental Assessment
P/E ratio of 26.3 (moderate relative to a 15-40x range); Price-to-book of 4.1x; PEG ratio of 1.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 15.4%; Return on assets of 6.3%; Net margin of 6.9%; Gross margin of 14.1%; Current ratio of 1.21 (tight short-term liquidity); Debt-to-equity of 0.92; Free cash flow per share is positive (7.23); Most recent quarter beat estimates by 2.2%; EPS growth accelerating (+1.6% -> +3.8% QoQ); Average YoY EPS growth of 20.8%; Analyst estimates rising over recent quarters
Get the Full ENSG Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime